Sanofi and GSK join forces to fight COVID-19
Sanofi and GSK announced on 14 April 2020 that they will work together on the development of a new, adjuvanted vaccine for COVID-19.
As the world’s leading vaccine manufacturer, our number one focus is to help develop a vaccine.
The collaboration for the first time brings together the scientific and manufacturing expertise and resources of two global scale vaccines specialists to address the urgent global need for a vaccine to protect people from this disease.
The two companies expect a candidate vaccine to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.
Hear from our CEO, Emma Walmsley
Emma discusses GSK's response to COVID-19 including our collaboration with Sanofi to develop an adjuvanted COVID-19 vaccine, our commitment to access and investment in long-term pandemic preparedness.
What is an adjuvanted vaccine?
An adjuvanted vaccine combines both an antigen and an adjuvant.
Find out more
GSK actions to support the global response to COVID-19
We are closely monitoring the COVID-19 pandemic and supporting global efforts to tackle the virus.
GSK FAQs on COVID-19
Our responses to frequently asked questions on COVID-19.
Guidance for clinical trial investigators
Conducting clinical research during the COVID-19 pandemic.
Supporting UK national effort to boost COVID-19 testing
GSK, AstraZeneca and University of Cambridge collaborate to support UK national effort to boost COVID-19 testing.